NEW YORK (Reuters Health) - Although all of the common strategies protect the upper gastrointestinal tract from the complications of nonsteroidal anti-inflammatory drugs (NSAIDs), popular over-the-counter analgesics such as Motrin (ibuprofen) or Aleve (naproxen), the combination of a COX-2 inhibitor and a proton pump inhibitor is associated with the largest reduction in gastrointestinal complications, according to a Canadian study published in the medical journal Gastroenterology.
COX-2 inhibitors treat pain and inflammation by selectively blocking the COX-2 enzyme, which prevents the production of chemical messengers that cause pain and swelling. They include drugs such as Celebrex (celecoxib). Two other COX-2 inhibitors (Vioxx and Bextra) were taken off the market in the U.S. because of safety concerns.
NSAIDs are non-specific inhibitors and also block chemical messengers that protect the stomach and play a role in blood clotting. Therefore, these drugs can cause bleeding and stomach irritation.
Proton pump inhibitors, such as Nexium (esomeprazole) and Prilosec (omeprazole), are a class of drugs that lower gastric acid levels. They are used to treat gastric disturbances and ulcers caused by the production of excessive gastric acid.
Using Manitoba's province-wide health database, the researchers, led by Dr. Laura Targownik of the University of Manitoba, Winnipeg, identified 1,382 users of either NSAIDs or COX-2-specific NSAIDs who had been hospitalized for an upper gastrointestinal condition from October 1995 through March 2004. Each subject was then matched for age and gender with as many comparison subjects or "controls" as possible from the database.
Compared with using a NSAID alone, the strategy of using a COX-2 inhibitor plus a proton pump inhibitor produced the greatest risk reduction in upper gastrointestinal complications - by 64 percent. This was followed by COX-2 inhibitor alone (49 percent), then non-selective NSAID plus proton pump inhibitor plus any dose of misoprostol (42 percent), non-selective NSAID plus proton pump inhibitor (33 percent), and lastly non-selective NSAID plus low-dose misoprostol (26 percent) also know by the trade name Cytotec.
